U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 61 - 70 of 111 results

mixture
Status:
Other

Class:
MIXTURE

mixture
Status:
Other

Class:
MIXTURE

mixture
Status:
Other

Class:
MIXTURE

mixture
Status:
Other

Class:
MIXTURE

mixture
Status:
Other

Class:
MIXTURE

mixture
Status:
US Previously Marketed
Source:
Spontin by Abbott
(1957)
Source URL:
First approved in 1957
Source:
Spontin by Abbott
Source URL:

Class:
MIXTURE

mixture
Status:
US Previously Marketed
Source:
Magoamycin by Pfizer
(1953)
Source URL:
First approved in 1953
Source:
Magoamycin by Pfizer
Source URL:

Class:
MIXTURE



Carbomycin is a complex mixture containing carbomycin A with a small portion of carbomycin B. Carbomycin is produced by Streptomyces halstedii and acts as an antibiotic. The drug was approved by FDA under the name Magna-terramycin (in combination with oxytetracycline) for the treatment of bacterial chronic respiratory diseases in chickens. Carbomycin exerts its antibacterial action by binding within the large ribosomal subunit and thus inhibiting the protein synthesis in bacterias.